Data completeness
2/8 — Basic
PROSTAPHLIN (oxacillin sodium) by Bristol Myers Squibb is clinical pharmacology intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Approved for the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROSTAPHLIN (Oxacillin Sodium) is a penicillinase-resistant penicillin antibiotic administered intravenously for treatment of infections caused by penicillin-producing staphylococci. It works by inhibiting bacterial cell wall biosynthesis, exerting bactericidal action during active microbial multiplication. The drug achieves peak serum levels within 5 minutes of IV administration and is rapidly excreted unchanged in urine.
Post-LOE
This legacy IV antibiotic operates in a mature, competitive generic market with minimal commercial growth opportunities and likely reduced team infrastructure.
Mechanism of Action
CLINICAL PHARMACOLOGY Intravenous administration provides peak serum levels approximately 5 minutes after the injection is completed. Slow I.V. administration of 500 mg gives a peak serum level of 43 mcg/mL after 5 minutes with a half-life of 20 to 30 minutes. Oxacillin sodium, with normal doses,…
Worked on PROSTAPHLIN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.